P4A hosts new webinar on - Is the UK losing its prime position in EU drug launches?

LONDON - June 10, 2021 - PRLog -- Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar to share insights on key emerging trend in launch strategy for new drugs within EU-5 for pharma/biotech manufacturers.

Post Brexit, the UK's position as a key country for drug launches is potentially under threat as biopharma companies are seeking to optimise their launch strategies by focusing on four EU countries – France, Germany, Italy and Spain.

The webinar titled ` EU-5 has become EU-4! What happened to the UK?' will be held on Wednesday, June 23^rd, 2021, at 11am EDT (4pm BST/UK).

Speakers include P4A's managing partner Sophie Schmitz and partner Akshay Kumar who will explore both sides of the argument, providing a balanced view.

The webinar will set out two main opinions: the first for including the UK as a priority market when developing launch strategies for orphan drugs and ATMPs (Advanced Therapies Medicinal Products); and the second against including the UK as a strategic priority.

By effectively exploring different arguments, the audience will get an objective perspective as to the value of UK prioritisation in developing orphan drugs and ATMPs launch strategies.

For more information or to register for this event, visit EU-5 has become EU-4-what happened to the UK? (https://partners4access.com/enlightened-opinion/webinars/...)

About Partners4Access:

Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.

As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.

The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.

For more information, please visit P4A's website: www.partners4access.com or email at contact@partners4access.com.

If you would like more information about this topic, please contact Aparna Krishnan at +44 7896246544 or email at akrishnan@partners4access.com.